Initially evaluated in controlled clinical trials for exacerbation reduction and OCS reduction. Later studied in open-label studies as shown below.
4.5-year open-label safety and efficacy study
For US HCPs
For US Healthcare Professionals
4.5-year open-label safety and efficacy study
Initially evaluated in controlled clinical trials for exacerbation reduction and OCS reduction. Later studied in open-label studies as shown below.
93% of patients from Trial 3 enrolled in the open-label extension trial3